NCT04877769View on ClinicalTrials.gov

Bronchopulmonary PK of AT-527 (R07496998)

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 25, 2021

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Healthy Volunteer Study
Interventions
DRUG

AT-527

administered twice daily (BID) for 2.5 days (5 doses in total)

Trial Locations (1)

NW10 7EW

Atea Study Site, London

Sponsors
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Atea Pharmaceuticals, Inc.

INDUSTRY

NCT04877769 - Bronchopulmonary PK of AT-527 (R07496998) | Biotech Hunter | Biotech Hunter